DNMT1 and cancer: The hybrid compound procainainamide-SAHA, which combines a DNMT inhibitor (Procainamide) with an HDAC1 inhibitor (SAHA), has been shown to be highly active against P. falciparum multidrug-resistant field strains and lacks cytotoxicity against human cancer cells [141].